benzalkonium

Small moleculeexperimental

Benzalkonium chloride, also known as BZK, BKC, BAC, alkyldimethylbenzylammonium chloride and ADBAC, is a type of cationic surfactant. It is an organic salt called a quaternary ammonium compound. In 2011, a large clinical trial designed to evaluate the efficacy of hand sanitizers based on different active ingredients in preventing virus transmission amongst schoolchildren was re-designed to exclude sanitizers based on benzalkonium chloride due to safety concerns. Benzalkonium chloride has been in common use as a pharmaceutical preservative and antimicrobial since the 1940s. While early studies confirmed the corrosive and irritant properties of benzalkonium chloride, investigations into the adverse effects of, and disease states linked to, benzalkonium chloride have only surfaced during the past 30 years. Benzalkonium chloride is classed as a Category III antiseptic active ingredient by the United States Food and Drug Administration. Ingredients are categorised as Category III when "available data are insufficient to classify as safe and effective, and further testing is required”. Benzalkonium chloride is excluded from the current United States Food and Drug Administration review of the safety and effectiveness of consumer antiseptics and topical antimicrobial over-the-counter drug products, meaning it will remain a Category III ingredient. The mechanism of bactericidal/microbicidal action is thought to be due to disruption of intermolecular interactions. This can cause dissociation of cellular membrane lipid bilayers, which compromises cellular permeability controls and induces leakage of cellular contents. Other biomolecular complexes within the bacterial cell can also undergo dissociation. Enzymes, which finely control a wide range of respiratory and metabolic cellular activities, are particularly susceptible to deactivation. Critical intermolecular interactions and tertiary structures in such highly specific biochemical systems can be readily disrupted by cationic surfactants. Benzalkonium chloride is a human skin and severe eye irritant. It is a suspected respiratory toxicant, immunotoxicant, gastrointestinal toxicant and neurotoxicant. — NCATS

Clinical trial activity

4 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Sep 30, 2013 (NCT01951391)

Timeline

No events for the selected filters.

Indications

Approved for

Mechanism of action

  • Unspecified targetSurfactant

    surfactant

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1
Mol. weight
318.57 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • benzalkonium
  • benzalkonium
  • benzalkonium
  • benzalkonium
  • benzalkonium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03686904Phase 4Sep 30, 2018Georgetown University, Next Science
NCT03323528Phase 4Feb 1, 2017Medice Arzneimittel Pütter GmbH & Co KG, University of Munster
NCT02012348N/ADec 31, 2013Colgate Palmolive, University of California, San Diego
NCT01951391N/ASep 30, 2013University of California, San Diego
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of California, San DiegoAcademic/Hospital2212013
Colgate PalmoliveFor profit1012013
Georgetown UniversityAcademic/Hospital1112018
Medice Arzneimittel Pütter GmbH & Co KGFor profit1112017
Next ScienceFor profit1012018
University of MunsterAcademic/Hospital1012017
6 organizations
Page 1 / 1